ºñÁê¾ó
Publications

Research Papers

°Ô½ÃÆÇ º¸±â
ÀÛ¼ºÀÚ ÀÛ¼ºÀÚ°ü¸®ÀÚ
³¯Â¥ 2023-07-12 14:13:27
Á¦¸ñ Three-year outcomes and predictors for full recovery in patients with early-stage psychosis
±â»ç ¸µÅ© http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9613771/pdf/41537_2022_Article_301.pdf
Three-year_outcomes_and_predictors_for_full_recovery_in_patients_with_early-stage_psychosis..JPG

Abstract

In the present study, various outcomes over 3-year period in patients with early stage psychosis including remission, recovery, relapse and medication adherence were investigated. Predictor for full recovery at year 3 was also examined. Three-year follow-up data in 534 patients with schizophrenia spectrum disorders (SSD) and psychotic disorder not otherwise specified (PNOS) were examined for overall outcome trajectories. The data of completers at year 3 (n = 157) were used to identify predictors for recovery using logistic regression. The rates of symptomatic remission and full recovery at 6-, 12-, 24-, and 36-month follow-up were 76.10, 69.20, 79.50, and 79.10%, and 22.80, 26.40, 28.60, and 39.60%, respectively. The rates of drop-out and relapse at 6-, 12-, 24-, and 36-month follow-up were 25.4, 29.5, 38.6, and 51.1%, and 3.7, 8.9, 19.0, and 38.9%, respectively. The rates of good adherence and prescription of Long-Acting Injectable Antipsychotics (LAIA) at 6-, 12-, 24- and 36-month follow-up were 87.8, 88.0, 91.9, and 93.9%, and 18.3, 21.7, 22.0, and 25.5%, respectively. Significant predictors for full recovery were duration of untreated psychosis (DUP), family intimacy and physical activity. We observed similar or better results on remission, recovery, and relapse rates compared to other previous studies. Effective psychosocial intervention should be provided to shorten the gap between remission and recovery rates and to address DUP, family issues, and exercise to enhance recovery.

÷ºÎÆÄÀÏ


ÃÑ °Ô½Ã¹° 54 ÆäÀÌÁö 1/4

   
°Ô½ÃÆÇ ¸®½ºÆ®
¹øÈ£ Á¦¸ñ ÆÄÀÏ ÀÛ¼ºÀÚ ³¯Â¥ Á¶È¸¼ö
54 Associations between post-traumatic stress diso... ÷ºÎÆÄÀÏ  °ü¸®ÀÚ 2023.09.21 192
53 Different topological patterns in structural co... ÷ºÎÆÄÀÏ  °ü¸®ÀÚ 2023.09.18 195
52 Medications for Psychosis: Dopamine Blockers an... ÷ºÎÆÄÀÏ  °ü¸®ÀÚ 2023.09.15 120
51 Validation of the Korean Version of the Communi... ÷ºÎÆÄÀÏ  °ü¸®ÀÚ 2023.07.28 113
50 Predictors of full recovery in patients with ea... ÷ºÎÆÄÀÏ  °ü¸®ÀÚ 2023.07.28 208
49 Development of the Korea-Polyenvironmental Risk... ÷ºÎÆÄÀÏ  °ü¸®ÀÚ 2023.07.12 54
48 The factor structure and clinical utility of cl... ÷ºÎÆÄÀÏ  °ü¸®ÀÚ 2023.07.12 51
ÇöÀç±Û Three-year outcomes and predictors for full rec... ÷ºÎÆÄÀÏ  °ü¸®ÀÚ 2023.07.12 37
46 Associations of Clozapine Use With Psychosocial... ÷ºÎÆÄÀÏ  °ü¸®ÀÚ 2023.07.12 115
45 DNA Methylation Profiles of the DRD2 and NR3C1 ... ÷ºÎÆÄÀÏ  °ü¸®ÀÚ 2023.07.12 35
44 Comparison of clinical features and 1-year outc... ÷ºÎÆÄÀÏ  °ü¸®ÀÚ 2023.07.12 36
43 Clozapine Optimization: A Delphi Consensus Guid... ÷ºÎÆÄÀÏ  °ü¸®ÀÚ 2023.07.12 80
42 An automatic analysis framework for FDOPA PET n... ÷ºÎÆÄÀÏ  °ü¸®ÀÚ 2023.04.18 193
41 Modeling Approach with Therapeutic Drug Monitor... ÷ºÎÆÄÀÏ  °ü¸®ÀÚ 2022.09.14 220
40 The Relationship Between Frontostriatal Connect... ÷ºÎÆÄÀÏ  °ü¸®ÀÚ 2022.07.25 226